Cabaletta Bio, Inc. (CABA)
Market Cap | 356.76M |
Revenue (ttm) | n/a |
Net Income (ttm) | -76.87M |
Shares Out | 48.28M |
EPS (ttm) | -1.72 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 842,674 |
Open | 7.77 |
Previous Close | 7.81 |
Day's Range | 7.39 - 7.90 |
52-Week Range | 6.90 - 26.35 |
Beta | 2.47 |
Analysts | Strong Buy |
Price Target | 35.78 (+384.17%) |
Earnings Date | Aug 8, 2024 |
About CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for CABA stock is "Strong Buy." The 12-month stock price forecast is $35.78, which is an increase of 384.17% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/w/s/press13-2506347.jpg)
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...
![](https://cdn.snapi.dev/images/v1/j/q/press2-2479194.jpg)
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 –
![](https://cdn.snapi.dev/images/v1/e/g/press14-2431608.jpg)
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials –
![](https://cdn.snapi.dev/images/v1/x/r/conf19-2426725.jpg)
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies...
![](https://cdn.snapi.dev/images/v1/r/k/press8-2334807.jpg)
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™ tria...
![](https://cdn.snapi.dev/images/v1/r/1/conf1-2295573.jpg)
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...
![](https://cdn.snapi.dev/images/v1/g/h/press13-2256654.jpg)
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...
![](https://cdn.snapi.dev/images/v1/7/b/press4-2252816.jpg)
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...
![](https://cdn.snapi.dev/images/v1/r/u/conf2-2213068.jpg)
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...
![](https://cdn.snapi.dev/images/v1/p/d/press9-2174838.jpg)
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
PHILADELPHIA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...
![](https://cdn.snapi.dev/images/v1/l/z/im-781397size1777777777777778width800-2174716.jpg)
Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy
Shares of Cabaletta Bio Inc. CABA, Gracell Biotechnologies Inc. GRCL and other smaller biotech companies involved in developing CAR-T cell therapies plunged Tuesday after the Food and Drug Administrat...
![](https://cdn.snapi.dev/images/v1/a/x/press15-2149263.jpg)
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first lupus clinical site actively recruiting patients...
![](https://cdn.snapi.dev/images/v1/i/d/press19-2141393.jpg)
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, an...
![](https://cdn.snapi.dev/images/v1/j/m/conf15-2127674.jpg)
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...
![](https://cdn.snapi.dev/images/v1/z/2/conf1-2068886.jpg)
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
PHILADELPHIA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapi...
![](https://cdn.snapi.dev/images/v1/u/c/conf19-2042795.jpg)
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September
PHILADELPHIA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...
![](https://cdn.snapi.dev/images/v1/i/c/press5-2016742.jpg)
Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
– Received second IND application clearance for CABA-201 in myositis as well as Fast Track Designation in SLE and LN –
![](https://cdn.snapi.dev/images/v1/y/8/press9-1984042.jpg)
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences –
![](https://cdn.snapi.dev/images/v1/p/o/conf16-1913982.jpg)
Cabaletta Bio to Present at the Jefferies Healthcare Conference
PHILADELPHIA, May 31, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies...
![](https://cdn.snapi.dev/images/v1/t/s/press7-1902184.jpg)
Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
PHILADELPHIA, May 22, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first c...
![](https://cdn.snapi.dev/images/v1/r/t/press7-1896466.jpg)
Cabaletta Bio Announces Pricing of Public Offering of Common Stock
PHILADELPHIA, May 17, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first c...
![](https://cdn.snapi.dev/images/v1/s/b/press15-1896025.jpg)
Cabaletta Bio Announces Proposed Public Offering of Common Stock
PHILADELPHIA, May 17, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first c...
![](https://cdn.snapi.dev/images/v1/w/j/press18-1891790.jpg)
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis
– Phase 1/2 trial for CABA-201 planned to initiate in patients with myositis at an initial dose that is equivalent to the dose used in a patient with myositis as reported in the recent Lancet Rheumat...
![](https://cdn.snapi.dev/images/v1/8/h/press15-1884613.jpg)
Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update
– IND application cleared within 30 days for clinical trial of CABA-201 in patients with LN and SLE and Fast Track Designation granted by the FDA for CABA-201 to deplete CD19-positive B cells and impr...